Lidman: Adjusting the acquisition plan does not constitute a significant restructuring adjustment.

Lidman announcement stated that the company plans to purchase 61.50% of the shares of Sanofi with cash, with a transaction price of 1.393 billion yuan, originally planned to acquire 70% of the shares at a price of 1.733 billion yuan. The performance commitment period has been adjusted to 2026-2028, with a cumulative committed net profit of not less than 512 million yuan, with a compensation cap of 545 million yuan. After the adjustment, the transaction price, total assets, net assets, and operating income do not exceed 20% of the original indicators, and do not affect production and operation, and do not constitute a major adjustment. On June 12th, the board of directors approved the adjusted plan, the independent directors agreed, and the independent financial advisor also believed that it did not constitute a major adjustment.